Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Monday, November 30, 2009, 8:10AM ET - U.S. Markets open in 1 hour and 20 minutes. Dow Down 1.48% Nasdaq  0.00%
BioMimetic Therapeutics Inc. (BMTI)On Nov 27: 10.88   0.00 (0.00%)  
MORE ON BMTI
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
BioMimetic Therapeutics Inc.
389-A Nichol Mill Lane
Franklin, TN 37067
United States - Map
Phone: 615-844-1280
Fax: 615-844-1281
Web Site: http://www.biomimetics.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Medical Instruments & Supplies
Full Time Employees:88

BUSINESS SUMMARY 
BioMimetic Therapeutics, Inc. develops and commercializes regenerative protein therapeutic-device combination products. Its products are primarily used for bone and tissue regeneration for the repair and healing of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage within orthopedic, spine, and sports injury applications. The company’s lead orthopedic product candidate includes Augment Bone Graft, for treating bone defects and injuries. It also has pre-clinical products, which include Augment Injectable Bone Graft for closed non-surgical fracture treatment; TBD for spine fusion; and Augment C for cartilage repair and Augment LT for ligament and tendon repair. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on BioMimetic Therapeutics Inc.


    CORPORATE GOVERNANCE 
    BioMimetic Therapeutics Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 51.4% of Russell 3000 companies and 56.4% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Dr. Samuel E. Lynch D.M.D., D.M.Sc.,, 49
    Founder, Chief Exec. Officer, Pres
    $ 583.00K $ 118.00K
    Mr. Lawrence E. Bullock , 53
    Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
    $ 318.00K $ 0
    Mr. Steven N. Hirsch , 57
    Chief Operating Officer, Head of Corp. Communications and Exec. VP of Orthopedics
    $ 403.00K $ 0
    Mr. Earl M. Douglas Esq, 46
    Gen. Counsel
    $ 277.00K $ 53.00K
    Dr. Russ Pagano Ph.D, 43
    VP of Regulatory and Clinical Affairs
    $ 260.00K $ 0
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis